ZA201403575B - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent - Google Patents
Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agentInfo
- Publication number
- ZA201403575B ZA201403575B ZA2014/03575A ZA201403575A ZA201403575B ZA 201403575 B ZA201403575 B ZA 201403575B ZA 2014/03575 A ZA2014/03575 A ZA 2014/03575A ZA 201403575 A ZA201403575 A ZA 201403575A ZA 201403575 B ZA201403575 B ZA 201403575B
- Authority
- ZA
- South Africa
- Prior art keywords
- halofenate
- urate
- gout
- patients
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/059394 WO2013066349A1 (en) | 2011-11-04 | 2011-11-04 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201403575B true ZA201403575B (en) | 2015-11-25 |
Family
ID=48192533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/03575A ZA201403575B (en) | 2011-11-04 | 2014-05-16 | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2773336A4 (enExample) |
| JP (1) | JP6202633B2 (enExample) |
| KR (1) | KR20140121383A (enExample) |
| CN (2) | CN104066427A (enExample) |
| AU (1) | AU2011380507B2 (enExample) |
| CA (1) | CA2859686C (enExample) |
| CL (1) | CL2014001155A1 (enExample) |
| IL (1) | IL232386A0 (enExample) |
| MX (1) | MX357507B (enExample) |
| NZ (1) | NZ624708A (enExample) |
| SG (1) | SG11201402032RA (enExample) |
| WO (1) | WO2013066349A1 (enExample) |
| ZA (1) | ZA201403575B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013245675B2 (en) * | 2012-04-13 | 2017-02-09 | Cymabay Therapeutics, Inc. | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent |
| TWI705812B (zh) * | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| JP6368756B2 (ja) * | 2016-10-20 | 2018-08-01 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法 |
| CN108014108A (zh) * | 2016-11-03 | 2018-05-11 | 江苏万邦生化医药股份有限公司 | lesinurad或其医药上可接受的盐在制备治疗或预防库欣综合征的药物中的应用 |
| JP7086980B2 (ja) * | 2017-10-26 | 2022-06-20 | 大塚製薬株式会社 | イノシトールリン酸含有組成物 |
| JP2023525631A (ja) * | 2020-03-15 | 2023-06-19 | アレン ダビドフ | ウイルス感染症及び健康上の影響の治療方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262118B1 (en) * | 1999-06-04 | 2001-07-17 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia |
| US7576131B2 (en) * | 1999-06-04 | 2009-08-18 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
| WO2011032175A1 (en) * | 2009-09-14 | 2011-03-17 | Nuon Therapeutics, Inc. | Combination formulations of tranilast and allopurinol and methods related thereto |
| US9023856B2 (en) * | 2011-11-04 | 2015-05-05 | Cymabay Therapeutics, Inc. | Methods for treating hyperuricemia in patients with gout using halofenate or halogenic acid and a second urate-lowering agent |
-
2011
- 2011-11-04 WO PCT/US2011/059394 patent/WO2013066349A1/en not_active Ceased
- 2011-11-04 SG SG11201402032RA patent/SG11201402032RA/en unknown
- 2011-11-04 NZ NZ624708A patent/NZ624708A/en not_active IP Right Cessation
- 2011-11-04 CA CA2859686A patent/CA2859686C/en not_active Expired - Fee Related
- 2011-11-04 EP EP11875114.8A patent/EP2773336A4/en not_active Withdrawn
- 2011-11-04 AU AU2011380507A patent/AU2011380507B2/en not_active Ceased
- 2011-11-04 CN CN201180076191.4A patent/CN104066427A/zh active Pending
- 2011-11-04 MX MX2014005400A patent/MX357507B/es active IP Right Grant
- 2011-11-04 JP JP2014541011A patent/JP6202633B2/ja not_active Expired - Fee Related
- 2011-11-04 CN CN201910004813.0A patent/CN109908124A/zh active Pending
- 2011-11-04 KR KR1020147015169A patent/KR20140121383A/ko not_active Abandoned
-
2014
- 2014-04-30 IL IL232386A patent/IL232386A0/en unknown
- 2014-05-02 CL CL2014001155A patent/CL2014001155A1/es unknown
- 2014-05-16 ZA ZA2014/03575A patent/ZA201403575B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2773336A1 (en) | 2014-09-10 |
| CA2859686A1 (en) | 2013-05-10 |
| JP2014532758A (ja) | 2014-12-08 |
| CN109908124A (zh) | 2019-06-21 |
| AU2011380507A1 (en) | 2014-05-29 |
| EP2773336A4 (en) | 2015-06-03 |
| CN104066427A (zh) | 2014-09-24 |
| NZ624708A (en) | 2015-11-27 |
| WO2013066349A1 (en) | 2013-05-10 |
| CA2859686C (en) | 2018-09-11 |
| MX357507B (es) | 2018-07-12 |
| MX2014005400A (es) | 2015-02-12 |
| SG11201402032RA (en) | 2014-09-26 |
| JP6202633B2 (ja) | 2017-09-27 |
| KR20140121383A (ko) | 2014-10-15 |
| AU2011380507B2 (en) | 2017-06-15 |
| CL2014001155A1 (es) | 2015-01-16 |
| IL232386A0 (en) | 2014-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2716669A4 (en) | METHOD OF MODIFYING SURFACE AND ELASTIC BODY HAVING MODIFIED SURFACE | |
| EP2627331A4 (en) | METHODS OF TREATING HYPERURICEMIA AND RELATED DISEASES | |
| EP2714172C0 (en) | DEPLOYMENT MECHANISM FOR BODY VESSEL INSERTION DEVICES | |
| PT3257546T (pt) | Método de preparação de cateter urinário pronto a utilizar | |
| SG11201401811WA (en) | Method for preventing and/or treating insulin resistance | |
| AP2013007249A0 (en) | Benzothiazole compounds and their pharmaceutical use | |
| ZA201300055B (en) | Treatment of gout and hyperuricemia | |
| PT2717692T (pt) | Ácidos tetra-hidrocanabinol-11-oicos para utilização no tratamento de doenças fibróticas | |
| DK2750705T3 (en) | Methods for effectively and rapidly desensitizing allergic patients | |
| PT2663864T (pt) | Método de avaliação de imunodiversidade e seu uso | |
| EP2739352A4 (en) | MULTIMODAL ELECTROTHERAPY PROCESS AND DEVICE | |
| ZA201307742B (en) | Method for manufacturing and utilizing ferritic-austenitic stainless steel | |
| FI20115893L (fi) | Menetelmä retention säätämiseksi ja menetelmässä käytettävä välituote | |
| EP2682248A4 (en) | INJECTION-FORMED BODY AND METHOD OF MANUFACTURING THE SAME | |
| PL2413718T3 (pl) | Zastosowanie kwasu arachidonowego do zmniejszenia ryzyka insulinooporności w późniejszym życiu | |
| SG11201402032RA (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent | |
| SG11201401272RA (en) | Method for manufacturing acrylic acid-based polymer and use for same | |
| SG11201406495UA (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
| SG10201503635WA (en) | Aildenafil citrate crystal form o, preparation method and use thereof | |
| PT2630475T (pt) | Método de diagnóstico e tratamento | |
| EP2863602A4 (en) | ENGINEER AND METHOD FOR CORRECTING SQUARE ERRORS | |
| EP2640376A4 (en) | CAFFEINE ACID DERIVATIVES AND THEIR USE FOR IMPROVING NEURONAL CELL-LIFECITY | |
| IL232385A (en) | Use of Halopnate or Cephalic Acid Compounds to Treat Hyperoricemia in Patients with Gout, Hyperoricemia, or Renal Disorder | |
| EP2773261A4 (en) | PRESSURE GAUGE FOR TESTING THE SPINAL REGION AND METHOD THEREOF | |
| SG10201609202PA (en) | Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent |